LondonPharma’s clinical trials so far have been primarily funded by directors, individual investors and Sarella Investments Limited.
Sarella Investments represents the investment interests of Frank Timiş who owns 85% of LondonPharma. He invested in LondonPharma in 2007.
Mr Timiş invested in the company because of its treatment for falciparum malaria (severe malaria) in children. Mr Timis is a mining and natural resources specialist, whose company, African Minerals, is the leading private employer in Sierra Leone, and as such he has seen many children in the region die from malaria.
Updated: 13/7/14Print this page